Lymphoplasmacytic lymphoma

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas like CLL and follicular lymphoma. Researchers will ask 250 Korean patients to fill out questionnaires about their well-being and anxiety. The goal is to underst…